From Cancer-Specific Breakthroughs to Ecosystem Leadership: AstraZeneca's China Blueprint for Oncology

Cancer has long ranked as the second leading cause of death globally, and China, with the highest number of new cases and deaths worldwide, stands at the forefront of the fight against cancer.¹. The industry is confronting a critical issue: how to continuously reduce the burden of mortality and improve patient survival and quality of life through genuine scientific breakthroughs.

This has never been an empty slogan, but a tough battle that must be won. According to data released by the National Cancer Center, China’s five-year cancer survival rate has risen from 40.5% in 2012–2015 to 43.7% in 2019–2021.², behind every percentage point lies the unwavering dedication and breakthroughs of countless researchers, clinicians, and pharmaceutical innovators.

In the battle against cancer, the role of multinational pharmaceutical companies is undergoing a profound transformation. In the past, the prevailing industry logic was “global R&D, introduction to China,” with the Chinese market primarily serving as a destination for the application and commercialization of innovative outcomes. Today, driven by the rise of local innovation capabilities in China and the continuous optimization of the policy environment, an increasing number of multinational pharmaceutical companies are positioning China as a global “source of innovation.” Their collaboration models are comprehensively upgrading from “in-licensing” to “joint R&D, co-incubation, and deep strategic partnerships.”

In this process, AstraZeneca has carved out a path centered on scientific innovation and supported by collaborative ecosystem development: from source discovery in the laboratory to real-world patient benefits at the clinical frontline; from synchronized global R&D to Chinese solutions that are increasingly demonstrating global leadership; and from drug innovation to end-to-end ecosystem co-creation—all committed to driving the reshaping of China’s oncology treatment landscape.

Currently, oncology clinical trials remain the core battleground for global drug development, but the treatment paradigm has undergone a fundamental shift: from traditional chemotherapy to cutting-edge technologies such as precision targeted therapy, immunotherapy, antibody-drug conjugates (ADCs), bispecific antibodies, and CAR-T cell therapy. Over the past two decades, 282 new active substances have been launched in the global oncology field, with 132 of them approved in just the last five years.³; it is projected that more than 100 novel cancer drugs will be launched on the market by 2030⁴. The pace of innovation in oncology is accelerating at a visibly rapid rate.

However, the value of oncology drug development lies not only in speed but more importantly in enabling patients to live longer and better. In 2022, there were 4.8247 million new cancer cases and 2.5742 million cancer-related deaths in China.⁵. Behind these figures lies the urgent desire of millions of Chinese families for more efficient, precise, and accessible treatment options. How far multinational pharmaceutical companies can go in the Chinese market largely depends on how profoundly they address these “localization” challenges.

Amidst this wave of industry innovation, AstraZeneca remains committed to the goals of extending overall patient survival and improving quality of life. Through its broad-spectrum strategy spanning “multiple cancer types and the full disease course,” the company has achieved continuous breakthroughs in six core therapeutic areas: lung cancer, breast cancer, urologic oncology, gastrointestinal cancers, gynecologic cancers, and hematologic malignancies. By delivering continuously iterated innovative solutions, AstraZeneca is steadily improving patient treatment outcomes and reshaping the landscape of oncology care.

In the fields of lung cancer, breast cancer, and urologic oncology, AstraZeneca has established a diversified and synergistic development landscape after more than 30 years of deep cultivation in China.

Lung Cancer, the "King of Cancers" in China with the Highest Incidence and Mortality Rates⁶, is one of the areas where AstraZeneca has made its deepest investments and maintains the most concentrated pipeline. From introducing the world’s first EGFR-targeted therapy to strategically laying out directions in targeted therapy, immunotherapy, antibody-drug conjugates (ADCs), and combination therapies for advanced lung cancer, AstraZeneca has built a robust pipeline covering all stages of disease and encompassing both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This effort is driving a paradigm shift in lung cancer treatment from the past era where “life was measured in months” toward “longer overall survival (OS),” helping to achieve the goals of curability in early-stage disease and prolonged survival in advanced-stage disease.

In the field of breast cancer, AstraZeneca has also established a profound presence, achieving a comprehensive precision medicine strategy that spans from advanced to early-stage disease, from later-line to first-line therapy, and covers all three major molecular subtypes. Furthermore, it has propelled HER2-low breast cancer into prominence as an indispensable new therapeutic subtype within precision oncology. Its antibody-drug conjugate (ADC) therapies have achieved seven consecutive approvals in China, with indicated indications spanning multiple therapeutic areas including breast cancer, gastric cancer, and lung cancer, while continuously exploring their potential in earlier lines of treatment and additional tumor types. In March this year, one such ADC therapy was approved in China for neoadjuvant treatment of HER2-positive early breast cancer, marking the first global approval of an ADC for this indication and offering new hope for clinical cure among high-risk patients.

In the field of urologic oncology, AstraZeneca has been deeply engaged in prostate cancer for over three decades, leading the transition of treatment from the endocrine era to the era of precision targeted therapy. The company continues to expand its pipeline through PARP inhibitors, AKT inhibitors, antibody-drug conjugates (ADCs), CAR-T cell therapy, and radioligand therapies, thereby promoting the standardized diagnosis and treatment of urologic tumors in China. In March 2026, AstraZeneca announced plans to build a production and supply base for radioligand therapeutics in Guangzhou, marking a strategic milestone in its next-generation therapy portfolio. This facility will manufacture an actinium-225-based radioligand therapeutic for the treatment of prostate cancer, providing patients with more personalized and precise treatment options.

In tackling the formidable challenges of gastrointestinal, gynecologic, and hematologic malignancies, AstraZeneca is leveraging its global R&D capabilities, collaborative development, and partnerships with Chinese innovators to accelerate the filling of therapeutic gaps in these areas.

Gastrointestinal cancers are a typical "Chinese stronghold." Data show that gastrointestinal cancers in China account for half of the top ten most common cancers, with particularly prominent disease and economic burdens.⁷AstraZeneca continues to break through treatment bottlenecks for refractory cancers, such as biliary tract cancer and gastric cancer, with its PD-L1 inhibitors and antibody-drug conjugate (ADC) therapies. In January 2026, a HER2-targeted ADC was approved for second-line treatment of advanced gastric cancer, becoming the first HER2-targeted ADC in China for this indication. In the field of liver cancer, AstraZeneca is also poised to introduce a “dual immunotherapy” regimen, offering patients novel treatment options.

As the Incidence of Gynecologic Cancers Continues to Rise in China⁸, therapeutic bottlenecks in the treatment of refractory cancers such as ovarian cancer and endometrial cancer urgently need to be broken. With the world’s first PARP inhibitor and the first immunotherapy regimen for primary advanced or recurrent endometrial cancer, AstraZeneca brings greater hope for survival to patients with ovarian and endometrial cancer. The company continues to promote the application of innovative therapies, accelerating the adoption of both monotherapies and combination regimens, with the aim of paving new pathways for the treatment of gynecologic tumors such as ovarian cancer.

According to statistics from the World Health Organization (WHO), lymphoma is one of the ten most common cancers worldwide and one of the malignant tumors with the fastest-growing incidence rate.⁹Currently, lymphoma treatment is advancing toward "functional cure." With its next-generation highly selective BTK inhibitor as the cornerstone, AstraZeneca is bringing hope for a high quality of life to patients with lymphoma. Looking ahead, AstraZeneca will introduce the new paradigm of "finite-duration therapy," pioneer cutting-edge modalities such as bispecific antibodies, trispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapy, and establish end-to-end cell therapy capabilities, making "cure" an increasingly attainable reality.

With a long-term strategic outlook, AstraZeneca has charted a clear innovation pathway. By 2030, the company expects to launch more than ten blockbuster oncology products and accelerate its deployment of next-generation therapies—represented by cutting-edge technologies such as cell therapy, radiopharmaceutical conjugates, novel immunotherapies, and T-cell engagers—thereby driving their transition from research and development to clinical application. With the recent official announcements of the Shanghai Cell Therapy Commercial Manufacturing and Supply Base and Innovation Center, as well as the Guangzhou Radiopharmaceutical Conjugate Manufacturing and Supply Base, AstraZeneca is extending its philosophy of “Science, Delivering Infinite Possibilities” from current medications to next-generation therapeutic arsenals, offering patients greater hope for cures.

At this stage, with the rapid rise of China’s innovative drug industry, multinational pharmaceutical companies are undergoing a fundamental shift in their strategies in China. Among the many multinational pharmaceutical companies operating in China, AstraZeneca stands out for its profound level of localization.

In 2024, AstraZeneca announced Shanghai as its fifth global strategic R&D center; in 2025, the Global R&D Beijing Strategic Center was officially launched, becoming AstraZeneca’s sixth global and second strategic R&D center in China. The establishment of these two core R&D hubs not only underscores its commitment to the Chinese market but also demonstrates its steadfast implementation of the “In China, For China, Benefit the World” strategy.

Currently, AstraZeneca’s R&D pipeline in China comprises over 250 projects, achieving 100% global synchronized development, with half focused on oncology. The company is conducting nearly 200 clinical trials in collaboration with approximately 500 hospitals across China, 30% of which are early-phase clinical trials. Having evolved from passive following to global parallel development, and now progressively leading in core therapeutic areas, China has become an indispensable and pivotal hub within AstraZeneca’s global innovation network.

Of greater industry significance, in the field of digestive tract cancers with high incidence in China—including gastric cancer, liver cancer, and biliary tract cancer—the AstraZeneca China R&D team has led more than 20 global clinical trials. This strategic portfolio not only enables Chinese patients to access cutting-edge global therapies at an early stage but also establishes Chinese clinical data as a core basis for global drug approvals.

Beyond this, AstraZeneca has never chosen to act as a lone player in China’s innovation ecosystem; instead, it has firmly positioned itself as a partner and enabler of Chinese innovative forces. Since 2023, AstraZeneca has entered into collaborations with 15 local Chinese innovative pharmaceutical companies, with the total potential value of these partnerships exceeding $43 billion, more than half of which focus on the oncology field.

From the $1.2 billion full acquisition of Gracell Biotechnologies, which set a precedent for multinational pharmaceutical companies’ wholly-owned mergers and acquisitions of Chinese biotech firms and paved a new path for the global expansion of Chinese innovation; to collaborations with a cohort of emerging domestic enterprises such as Connoa Therapeutics, Harbour BioMed, and Lixin Pharma, introducing cutting-edge pipelines including CLDN18.2 ADCs and GPRC5D-targeted ADCs to rapidly enhance its next-generation innovative therapy portfolio; and further to the management of the AstraZeneca CICC Healthcare Industry Fund, with assets under management exceeding RMB 4 billion, focusing on biopharmaceuticals, medical devices, diagnostic services, and digital health, covering the entire value chain from early-stage R&D to commercialization to support the development and global expansion of local enterprises—AstraZeneca has achieved bidirectional empowerment between local innovation and global resources, injecting sustained momentum into the high-quality development of China’s pharmaceutical innovation industry.

In January 2026, AstraZeneca sent another strong signal by announcing plans to invest over RMB 100 billion in China before 2030. This investment aims to expand its footprint in pharmaceutical manufacturing and R&D, fully leverage China’s scientific research strengths and advanced manufacturing capabilities, and rely on synergistic collaboration between the Chinese and UK healthcare ecosystems to deliver cutting-edge innovative therapies to patients in China and worldwide. This strategic investment of hundreds of billions not only demonstrates long-term confidence in the Chinese market but also firmly implements the strategy of “China-driven innovation for the world.”

The ultimate breakthrough in science must ultimately translate into tangible accessibility for patients.

Latest cancer burden statistics show that China’s cancer incidence rate is close to the global average, but its mortality rate is significantly higher than both the global average and that of high-income countries. The loss of healthy life years due to cancer in China is nearly twice the global average.

The “Healthy China Initiative – Implementation Plan for Cancer Prevention and Control (2023–2030)” explicitly sets a target of achieving an overall five-year cancer survival rate of 46.6% in China by 2030. Cancer prevention and control has become a major national priority. Enhancing access to innovative therapies and promoting early screening, early diagnosis, and early treatment are core actions through which AstraZeneca supports the cancer prevention and control goals of Healthy China 2030.

At the level of standardized diagnosis and treatment and whole-course disease management, AstraZeneca promotes the standardization and normalization of oncology care through its end-to-end layout. On one hand, it actively supports the construction of multidisciplinary collaboration platforms to advance standardized diagnosis and treatment, building a comprehensive diagnostic and therapeutic ecosystem covering “diagnosis–treatment–management.” This includes actively supporting medical institutions and industry associations in establishing and popularizing prostate cancer screening standards; supporting industry societies, associations, and academic institutions in conducting clinical and health economics research; launching public welfare campaigns for early screening education to enhance public awareness; and participating in and supporting the establishment of specialized breast disease centers*. On the other hand, it continuously supports patient care initiatives, having sponsored the “Gu5 Life” patient care program* in the field of lung cancer for ten consecutive years and the “Health Has Her” patient care program* in the field of breast cancer for four consecutive years. By mobilizing diverse social forces, AstraZeneca provides patients with sustained encouragement and support, helping them regain vitality and renew their lives.

In enhancing drug accessibility, AstraZeneca has actively responded to national policies by establishing a multi-tiered payment system that integrates medical insurance, inclusive commercial health insurance, and charitable assistance. With the official implementation of the 2026 edition of the National Reimbursement Drug List (NRDL), two of AstraZeneca’s innovative drugs for treating breast cancer and lymphoma were included in the NRDL for the first time, while three innovative drugs for lung cancer and gynecological tumors gained approval for three additional indications within the NRDL. The continuous expansion of coverage for innovative therapies ensures that more patients have access to and can afford high-quality innovative medicines.

Science Knows No Bounds, Life Comes First. “To ensure cancer is no longer a leading cause of death”—this is not merely AstraZeneca’s narrative ambition, but also its mission and vision after more than three decades of deep commitment in China. From continuously redefining the oncology treatment landscape through disruptive scientific innovation, to evolving Chinese innovative solutions from global synchronicity to global leadership, and further to driving continuous transformation in diagnosis and treatment through a comprehensive ecosystem, AstraZeneca is aligning its all-encompassing, multi-level, and long-term strategic layout with national strategies, steadily turning its vision into reality.

*Third-Party Projects

Disclaimer: The above content is corporate news and is not intended for any promotional purposes.

References:

1. Filho AM, Laversanne M, Ferlay J, et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156(7):1336-1346. doi:10.1002/ijc.35278

2. Hongmei Zeng, Rongshou Zheng, Kexin Sun, etc. Cancer survival statistics in China 2019–2021: a multicenter, population-based study,Journal of the National Cancer Center,Volume 4, Issue 3,2024,Pages 203-213,ISSN 2667-0054,https://doi.org/10.1016/j.jncc.2024.06.005.

3. Global Oncology Trends 2025: Adopting New Therapies as Modalities Shift and Expenditures Rise

4. IQVIA, Global Oncology Trends 2025

5. JNCC: National Cancer Center Releases 2022 Data on the Burden of Malignant Tumors in China - MedSci.cn

6. JNCC: National Cancer Center Releases 2022 Data on the Burden of Malignant Tumors in China - MedSci.cn

7. Analysis of the Disease Burden of Digestive System Cancers in the Chinese Population - Chinese Journal of Epidemiology

8. caca.org.cn/system/2024/04/30/030090590.shtml

9. Accelerated Breakthroughs in Lymphoma Diagnosis and Treatment: Innovative Drugs and Standardized Care Build a Health Defense Line_News Channel_CCTV.com (cctv.com)